Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani

By Santos W.R.   Paraguai de Souza E.   Palatnik M.   Palatnik de Sousa C.B.  

Vaccine, Vol. 17, Iss. 20, 1999-06 ,pp. : 2554-2561

Elsevier

Access to resources Recommend Favorite

Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protects BALB/c and C57BL/6 mice against cutaneous leishmaniasis

By Pinto E.F.   de Mello Cortezia M.   Rossi-Bergmann B.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3534-3541

Elsevier

Access to resources Recommend Favorite

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis

By Gonzalo R.M.   del Real G.   Rodriguez J.R.   Rodriguez D.   Heljasvaara R.   Lucas P.   Larraga V.   Esteban M.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1226-1231

Elsevier

Access to resources Recommend Favorite

Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani

By Sukumaran B.   Tewary P.   Saxena S.   Madhubala R.  

Vaccine, Vol. 21, Iss. 11, 2003-03 ,pp. : 1292-1299

Elsevier

Access to resources Recommend Favorite

Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice

By Ramrez J.R.   Gilchrist K.   Robledo S.   Sepulveda J.C.   Moll H.   Soldati D.   Berberich C.  

Vaccine, Vol. 20, Iss. 3, 2001-11 ,pp. : 455-461

Elsevier

Access to resources Recommend Favorite